Hepatitis b drug combo study halted early – what we know
NCT ID NCT05330455
First seen May 14, 2026 · Last updated May 21, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug (GSK3965193) for chronic hepatitis B, first in healthy volunteers and then in people with the infection. Some participants also received a second drug (bepirovirsen). The goal was to check safety and how well the drugs lower the virus. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Calgary, Alberta, T2N 4Z6, Canada
-
GSK Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
-
GSK Investigational Site
Grenoble, 38043, France
-
GSK Investigational Site
Nantes, 44000, France
-
GSK Investigational Site
Rennes, 35033, France
-
GSK Investigational Site
Milan, 20122, Italy
-
GSK Investigational Site
Monza MB, 20900, Italy
-
GSK Investigational Site
Daegu, 700-721, South Korea
-
GSK Investigational Site
Pusan, 49241, South Korea
-
GSK Investigational Site
Seoul, 05505, South Korea
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom
-
GSK Investigational Site
London, SW17 0QT, United Kingdom
-
GSK Investigational Site
London, W2 1NY, United Kingdom
Conditions
Explore the condition pages connected to this study.